With a background of 13 years’ experience as a physician and 20 years in basic research, Dr. Li co-founded Ractigen Therapeutics in 2016. Prior to that, he held an Associate Professor in Residence position in the University of California, San Francisco (UCSF) until 2015 and a specially appointed Professor position at Peking Union Medical College Hospital of Chinese Academy of Medical Sciences until 2017. Dr. Li is globally recognized for his groundbreaking work on RNA-mediated gene activation (RNAa), a technology that has advanced into human clinical trial. He has authored or co-authored over 80 publications which have received over 10000 citations. He is the inventors of 4 issued and 2 pending US patents. He received multiple research grants from both governmental and non-governmental organizations including a prestigious NIH Director's Transformative R01 (T-R01) Award in 2009. He is an invited speaker at many national and international conferences, universities and companies around the world.